Pharma Stocks
-
Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Revenue And New Oncology Data Release
In late February 2026, Jazz Pharmaceuticals reported fourth‑quarter 2025 revenue of US$1,197.93 million and net income of US$203.45 million, contributing…
Read More » -
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative
Amneal Pharmaceuticals (AMRX) has just posted its FY 2025 numbers, with Q4 revenue of US$814.3 million and basic EPS of…
Read More » -
Should Merck’s (MRK) New STK-012 Keytruda Lung Cancer Combo Strategy Require Action From Investors?
In late February 2026, Synthekine announced a collaboration and supply agreement with Merck to test STK-012 alongside Keytruda and chemotherapy…
Read More » -
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narratives Despite Low 9.5x P/E
Amphastar Pharmaceuticals (AMPH) closed out FY 2025 with Q4 revenue of US$183.1 million and basic EPS of US$0.53, alongside net…
Read More » -
Indivior’s Strong 2025 Results and US$400 Million Buyback Might Change The Case For Investing In Indivior Pharmaceuticals (INDV)
In February 2026, Indivior Pharmaceuticals, Inc. reported fourth-quarter 2025 sales of US$358 million and net income of US$102 million, alongside…
Read More » -
Terns Pharmaceuticals (TERN) Valuation Check After Strong Recent Share Price Run And CML Narrative Shift
Terns Pharmaceuticals (TERN) has drawn attention after recent trading, with the stock closing at US$40.92. For investors, the clinical stage…
Read More » -
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)…
Read More » -
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.97 per…
Read More » -
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the fourth quarter of 2025, beating the Zacks Consensus…
Read More » -
4597.T stock: Solasia Pharma JPX +10% to JPY 33.00 on 54.51M volume: catalysts 26 Feb 2026
Solasia Pharma K.K. (4597.T) closed higher on 26 Feb 2026, rising 10.00% to JPY 33.00 on heavy volume of 54,508,500.00…
Read More »